research use only
Cat.No.S4817
|
In vitro |
DMSO
: 53 mg/mL
(198.99 mM)
Ethanol : 53 mg/mL Water : 35 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 266.34 | Formula | C14H22N2O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 29122-68-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Tenormin, Normiten, Blokium | SMILES | CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
β1 receptor
(Cell-free assay) 0.25 μM(Kd)
β2 receptor
(Cell-free assay) 1 μM(Kd)
|
|---|---|
| In vivo |
In clinical pharmacokinetics studies, atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. After oral administration elimination half life of atenolol is calculated from 6 to 9 h. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia while no correlation is found between plasma levels of atenolol and blood pressure lowering activity of the drug.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2025-12-17)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07268170 | ENROLLING_BY_INVITATION | Coronary Arterial Disease (CAD); Ischemic Heart Disease (IHD) |
Gødstrup Hospital |
2025-12-15 | PHASE2; PHASE3 |
| NCT02560805 | RECRUITING | Stress Disorders, Post-Traumatic |
Emory University |
2015-10 | PHASE2 |
| NCT04905277 | COMPLETED | Healthy |
Sundeep Khosla, M.D. |
2021-07-27 | PHASE2 |
| NCT04914234 | RECRUITING | Hypotension Drug-Induced |
Damanhour Teaching Hospital |
2025-08-01 | PHASE4 |
| NCT06505668 | UNKNOWN | Treatment Resistant Schizophrenia; Clozapine Adverse Reaction; Heart Rate Variability; Tachycardia |
All India Institute of Medical Sciences, Bhubaneswar |
2023-08-01 | |
| NCT06670690 | COMPLETED | Intraoperative Bleeding |
Menoufia University |
2023-09-01 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.